share_log

Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target

Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target

Wedbush重申對Compass Therapeutics的跑贏大盤評級,維持8美元的價格目標。
Benzinga ·  08/07 10:35  · 評級/大行評級

Wedbush analyst Robert Driscoll reiterates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and maintains $8 price target.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論